Superior thermal performance and enhanced usability for PCR applications, such as sequencing, cloning, and genotyping.
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of its PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers, designed to support PCR applications in basic and translational research, process development, and quality control.
The PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers are the latest additions to the Bio-Rad portfolio of conventional PCR thermal cyclers. The PTC Tempo Thermal Cyclers are built with a refreshed, intuitive user interface and flexible connectivity features for streamlining protocol management, including monitoring capabilities on the BR.io cloud platform. Engineered to maintain superior thermal performance, the PTC Tempo Thermal Cyclers offer scientists the flexibility to scale within the laboratory.
The PTC Tempo 48/48 Thermal Cycler features separate dual blocks with manual lids, allowing two independent protocols to run simultaneously. Optimized for laboratories working with higher sample throughput, the PTC Tempo 384 Thermal Cycler features a motorized lid for automation compatibility and integration with robotics.
“We are excited to bring the PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers to the market, expanding the PTC Tempo family and completing the refresh of the 1000-Series Thermal Cyclers for research use,” said Steven Blakely, Senior Director of Marketing for Bio-Rad’s gene expression business. “These PCR instruments offer enhanced usability with features designed to support academic, commercial, and biopharma labs.”
Please visit bio-rad.com/ptc-tempo for more information about the PTC Tempo Thermal Cycler.
BIO-RAD is a trademark of Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,200 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements are based on assumptions and expectations of future events that are subject to risks and uncertainties, which could cause actual results to vary materially from the plans, goals, and expectations expressed in or indicated by the forward-looking statements. These risks and uncertainties include the impact of the COVID-19 pandemic, supply chain risks, global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, reductions in government funding and the capital spending programs of our customers, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.